Hengrui Pharmaceuticals and startup Kailera Therapeutics reported phase 3 results from China positioning their once-weekly injectable dual GLP-1/GIP receptor agonist as a potent obesity treatment. Patients experienced an average 18% weight loss after 48 weeks, with high rates of sustained and significant reductions. Safety data showed mostly mild gastrointestinal side effects. Hengrui plans a China regulatory filing, and Kailera will initiate global trials at higher doses and extended durations. This achievement elevates China-originated drugs' impact in the obesity space, challenging established competitors like Eli Lilly's Zepbound.